Company: FLDDW
Filing Date: 2025-07-11
Form Type: S-1
Source: 0001213900-25-062935
Chunk: 351

Company: Fold Holdings, Inc.
Filing Date: 2025-07-11
Form: S-1
Chunk 351
---
 allows the Investor the option to convert the December 2024 Investor Note in exchange for 1,739,130shares of common stock. The March 2025 Investor Note contains a conversion feature that allows the Investor the option to convert in exchange for 3,702,360shares of common stock. The effect of the incremental common shares issuable upon a conversion of these notes would be anti -dilutivebased on Fold’s average share price for three months ended March 31, 2025 and are therefore excluded from the loss per share calculation. (3) As of March 31, 2025, Fold had (1) 12,434,658public warrants related to legacy FTAC Emerald at an exercise price of $ 11.50; (2) 869,565Series A and 869,565Series C Warrants outstanding related to the December 2024 Investor Note, at an exercise price of $ 12.50and $ 11.50per share, respectively; and (3) 925,590Warrants outstanding related to the March 2025 Investor Note at an exercise price of $ 15.00. These warrants are considered anti -dilutivebased on Fold’s average share price for three months ended March 31, 2025 and are therefore excluded from the loss per share calculation. 18. SUBSEQUENT EVENTS The Company evaluated subsequent events, if any, that would require an adjustment to the Company’s financial statements or require disclosure in the notes to the financial statements through May 15, 2025, the date the financial statements were available to be issued. Where applicable, the notes to these financial statements have been updated to discuss significant subsequent events which have occurred. On June16, 2025, the Company entered into the Equity Purchase Facility Agreement, dated as of June16, 2025 (“Facility”) with SZOP Opportunities I, LLC (“SZOP”), pursuant to which SZOP committed to purchase, subject to certain conditions and limitations, up to $ 250,000,000(the “Commitment”) in newly issued shares of the Company’s common stock, par value $ 0.0001per share (“Common Stock”). Pursuant to the terms and subject to the conditions of the Facility, at any time until the Facility is terminated, the Company, in its sole discretion, has the right, but not the obligation, to issue and sell to SZOP, and SZOP must subscribe for and purchase from the Company, Shares (“Advance